NRAS and malignant colon neoplasm: Compared with colon cancer rectal cancer, KRAS/NRAS/BRAF have a lower mutation rate in gastric cancer, furthermore, there is no consistent conclusion on the role of KRAS/NRAS/BRAF mutations in gastric cancer (40–43).